Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Great Books and Resources Worth Reading – June 2013

We hope this regional recommended reading list will assist you finding information about living with cancer. If you have read books that you would like to share with other readers, please be in … Continue reading

June 27, 2013

Canadian Partnership Against Cancer Call for Applications: Advisory Groups

On behalf of the Canadian Cancer Action Network (CCAN), we would like to take this opportunity to make you aware of the Canadian Partnership Against Cancer Call for Applications: Advisory … Continue reading

June 21, 2013

Pazopanib Improves Progression-Free Survival in Advanced Ovarian Cancer

“Adding pazopanib (Votrient, GlaxoSmithKline) to the standard treatment regimen increased progression-free survival in women with advanced ovarian cancer. According to new data, pazopanib given after successful treatment with surgery and … Continue reading

June 21, 2013

Treatment with Pazopanib After Successful Chemotherapy Delays the Recurrence of Advanced Ovarian Cancer

2013 Annual Meeting of the American Society of Clinical Oncology. Abstract LBA5503. Presented June 1, 2013. http://www.cancer.net/cancer-news-and-meetings/asco-annual-meetings/research-summaries/treatment-pazopanib-after-successful-chemotherapy-delays-recurrence-advanced-ovarian-cancer?et_cid=31861718&et_rid=463565042&linkid=http%3a%2f%2fwww.cancer.net%2fcancer-news-and-meetings%2fasco-annual-meetings%2fresearch-summaries%2ftreatment-pazopanib-after-successful-chemotherapy-delays-recurrence-advanced-ovarian-cancer Women with advanced ovarian cancer or a related gynecologic cancer who receive treatment … Continue reading

June 21, 2013

Ovarian Cancer Focus in Current Oncology

This issue of Current Oncology contains four articles on the subject of the role of bilateral salpingectomy in preventing high-grade serous ovarian carcinoma. To the uninitiated, that idea may seem … Continue reading

June 21, 2013

Current Standards of Care for Chemotherapy of Optimally Cytoreduced Advanced Epithelial Ovarian Cancer

Highlights Platinum-taxane chemotherapy remains the standard of care for the primary treatment of optimally cytoreduced advanced epithelial ovarian cancer. Primary intraperitoneal cisplatin-based chemotherapy has been shown to improve survival in … Continue reading

June 21, 2013

Pelvic Inflammatory Disease and Risk of Invasive Ovarian Cancer and Ovarian Borderline Tumors

“Our results suggest that a history of PID is associated with an increased risk of ovarian borderline tumors, which may support the hypothesis that inflammation is an etiological factor.”  Christina … Continue reading

June 21, 2013

Survival Impact of Complete Cytoreduction to No Gross Residual Disease for Advanced-Stage Ovarian Cancer: A Meta-Analysis

Highlights The proportion of patients left with no gross residual disease is independently predictive of survival. The proportion of patients receiving intraperitoneal chemotherapy is a significant predictor of cohort survival … Continue reading

June 21, 2013

Endometrial and Ovarian Cancer in Women with Lynch Syndrome: Update in Screening and Prevention

Women with Lynch syndrome have an additional need to address the substantial increased lifetime risk of endometrial and ovarian cancer. Endometrial or ovarian cancer can be the presenting cancer in … Continue reading

June 21, 2013

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada